The FDA's regulatory handling of leucovorin represents a pivotal case study in the evolving relationship between evidence standards, drug repurposing initiatives, and biotech investment calculus—with significant implications that extend well beyond this single therapeutic.

The Leucovorin Regulatory Trajectory: From Broad Claims to Narrow Approval

On September 22, 2025, FDA Commissioner Marty Makary announced that the agency would approve leucovorin calcium tablets for patients with cerebral folate deficiency (CFD), stating that "hundreds of thousands of kids, in my opinion, will benefit" and that the FDA was using "gold standard science and common sense to deliver for the American people"FDA Takes Action to Make a Treatment Available for Autism Symptoms | FDAfda . The announcement positioned leucovorin as potentially transformative for children with autism spectrum disorder, with the FDA having "conducted a systematic analysis of literature published between 2009-2024, including published case reports with patient-level information, as well as mechanistic data"FDA Takes Action to Make a Treatment Available for Autism Symptoms | FDAfda .

By March 10, 2026, the regulatory outcome had narrowed dramatically. The FDA approved leucovorin specifically for "cerebral folate deficiency in adult and pediatric patients who have a confirmed variant in the folate receptor 1 gene (CFD-FOLR1)"FDA Approves First Treatment for Patients with Cerebral Folate Transport Deficiency | FDAfda —an ultra-rare genetic condition estimated to affect fewer than 1 in 1 million people, with fewer than 50 cases ever identified worldwideFDA approves leucovorin for rare genetic condition, but not for autismcnn . Senior FDA officials told reporters that "the agency does not have sufficient evidence to support the use of leucovorin for autism symptoms across the spectrum"FDA declines to approve leucovorin for autism despite Trump team hypeyoutube +1.

This regulatory narrowing occurred against a backdrop of scientific controversy. The largest study demonstrating leucovorin's efficacy in autism was retracted by the European Journal of Pediatrics on January 29, 2026Autism Trial Supporting FDA-Touted Drug Is Retracted | MedPage Todaymedpagetoday . The Coalition of Autism Scientists had warned that existing trials "are methodologically weak, use questionable statistical approaches, and do not justify clinical recommendations"'Highly concerning': Major medical groups react to Trump's Tylenol, autism claimgo . The American Academy of Pediatrics concluded that "current evidence is insufficient to support prescribing leucovorin for autism in the absence of CFD"Frequently Asked Questions (FAQs) for Pediatricians and other Prescribing Pediatric Clinicians: Leucovorin Use in Autism and Cerebral Folate Deficiencyaap +1.

Despite the narrowed indication, the episode had measurable real-world impact: a Lancet study found that leucovorin prescriptions for children aged 5 to 17 rose 71% in the three months following President Trump's September press conferenceFDA finds little evidence that a generic drug can help people with autismyahoo .

The Evidence Standard Question: Literature Review Without Traditional Trials

The leucovorin case is remarkable for its evidentiary basis. The FDA's approval relied on "published case reports provided patient-level data on over 40 patients, including both adults and pediatric patients, with genetically confirmed CFD due to variants in the FOLR1 gene who were treated with oral leucovorin"Federal Register/Vol. 90, No. 183/Wednesday, September ...govinfo . Clinical outcomes were "compared to the known natural history of CFD due to variants in the FOLR1 gene as historic control," and the agency found that "the majority of patients demonstrated substantial improvement of symptoms of CFD that would not be expected when compared to the natural history"Federal Register/Vol. 90, No. 183/Wednesday, September ...govinfo .

This approach—systematic literature review rather than prospective Phase 3 trials—represents a departure from conventional drug approval pathways. GSK confirmed it would submit a supplemental New Drug Application (sNDA) "at the FDA's request as part of the agency's initiative to investigate opportunities to repurpose older medications for the treatment of chronic diseases"GSK to submit label update for Wellcovorin (leucovorin) at US FDA’s request | GSKgsk . The FDA itself characterized the action as reflecting "the FDA's commitment to identify opportunities to repurpose drugs to treat chronic diseases"FDA Takes Action to Make a Treatment Available for Autism Symptoms | FDAfda .

The 505(b)(2) regulatory pathway has historically permitted reliance on "published literature" as a source of evidence, where sponsors can "establish a 'bridge' to each source necessary for approval (scientific relevance to the proposed product)"[PDF] overview of the 505(b)(2) regulatory pathway for new drug applicationsfda . Under this pathway, 505(b)(2) applicants "can partially rely on FDA's previous safety and efficacy data, along with additional publicly available data on efficacy in their submission," potentially allowing developers to "bypass nonclinical or clinical studies, or both, depending on available data"[PDF] Regulatory Actions to Advance Generic Drug Repurposingduke .

However, even under 505(b)(2), "a new label indication claim must demonstrate substantial evidence of effectiveness, which under certain circumstances can be accomplished with one adequate and well-controlled clinical investigation and confirmatory evidence"[PDF] Regulatory Actions to Advance Generic Drug Repurposingduke . The leucovorin approval—based solely on case reports and mechanistic data without any new prospective clinical trials—tests the boundaries of what constitutes "substantial evidence."

Broader Regulatory Context: The One-Trial Shift and Real-World Evidence Expansion

The leucovorin case cannot be evaluated in isolation from the FDA's broader regulatory evolution under Commissioner Makary. On February 19, 2026, the FDA formally announced that "one adequate and well-controlled study, combined with confirmatory evidence, will serve as the basis of marketing authorization of novel products"Inside Biotech: FDA says ‘one and done’ — what it means for biotech globallyproactiveinvestors . This policy "marks a formal end to the longstanding 'two-trial' standard that had guided regulatory submissions for decades"Inside Biotech: FDA says ‘one and done’ — what it means for biotech globallyproactiveinvestors .

Commissioner Makary and CBER Director Dr. Vinay Prasad argued that "the science has evolved—with more sophisticated trial designs, better biomarkers, modern statistical methods and richer external evidence sources—and that regulators and sponsors alike should concentrate resources on making one excellent study instead of two adequate ones"Inside Biotech: FDA says ‘one and done’ — what it means for biotech globallyproactiveinvestors .

Simultaneously, the FDA expanded its acceptance of real-world evidence. In new guidance, the agency stated it will "accept RWE without requiring that identifiable individual patient data collected from real-world data sources always be submitted in a marketing submission"FDA Eliminates Major Barrier to Using Real-World Evidence in Drug and Device Application Reviews | FDAfda . Commissioner Makary characterized this as "removing unnecessary barriers that have prevented us from using powerful real-world evidence to get life-changing treatments to patients faster"FDA Eliminates Major Barrier to Using Real-World Evidence in Drug and Device Application Reviews | FDAfda .

The historical trajectory supports the leucovorin case as part of a longer pattern. Between 2016 and 2024, there was "a linear decline in the mean number of studies used per approval," with the mean decreasing from 3.41 studies in 2016 to 1.50 by 2022Changes in Evidence Used for FDA Novel Drug Approvals Following the Implementation of the 21st Century Cures Act | bioRxivbiorxiv . By 2024, "69.4% of products were approved on the basis of a single trial, and only 5.6% were approved on the basis of 3 or more trials"Changes in Evidence Used for FDA Novel Drug Approvals Following the Implementation of the 21st Century Cures Act | bioRxivbiorxiv .

Implications for Off-Label Drug Repurposing Pathways

The leucovorin episode illuminates several tensions in the regulatory treatment of off-label uses:

The FDA-Initiated Relabeling Model

Unlike typical 505(b)(2) applications where sponsors identify and pursue new indications, the leucovorin case involved the FDA requesting that GSK update the label. As one analysis noted, "in this case with leucovorin, there's a significant departure from the normal approval process for two reasons. First, the FDA itself prompted GSK to pursue an indication change. And second, the evidence base for leucovorin in autism largely consists of small, heterogeneous studies"Leucovorin, Autism, and the FDA: Separating Political Promises from Scientific Proofsubstack .

This model—where the FDA identifies repurposing opportunities and solicits sponsor participation—could theoretically accelerate drug repurposing but raises questions about the separation between regulatory judgment and promotional advocacy.

Evidence Thresholds for Literature-Based Approvals

The FDA's acceptance of case report data without new clinical trials creates precedent questions for future repurposing efforts. The agency acknowledged that CFD "has also been reported in a broader patient population with neuropsychiatric symptoms, including autistic features, and detectable serum autoantibodies to the folate receptor alpha; however, there are limitations on the available data for the use of leucovorin in this population and additional studies are needed to assess safety and efficacy"FDA Takes Action to Make a Treatment Available for Autism Symptoms | FDAfda .

This acknowledgment of data limitations for the broader autism population, while still proceeding with the narrow CFD-FOLR1 approval, suggests the FDA may be establishing a tiered evidence framework where ultra-rare conditions with clear mechanistic rationale can be approved on case report evidence, while broader indications require traditional trials.

Manufacturer Communication Constraints

The January 2025 FDA guidance on off-label communications clarifies that manufacturer-initiated communications about off-label uses must be "scientifically sound" and accompanied by "the current approved labeling, additional statements (about the approved use, that the unapproved use has not been approved by FDA, and that the safety and effectiveness of the medical product for the unapproved use(s) has not been established)"The January 6, 2025 Final Guidance On Off-Label Use | Drug & Device Lawdruganddevicelawblog . This framework limits manufacturers' ability to promote off-label uses even when evidence accumulates, potentially constraining the commercial viability of repurposed drugs without formal label expansions.

Investment Implications: Quantifying the Regulatory Risk-Reward Calculus

Venture Capital Sentiment and FDA Stability

The January 2026 Incubate Policy Lab survey of life sciences venture capital investors revealed that "policy—not just scientific potential—is playing an increasing role in how investors assess biotech opportunities"Incubate Investor Survey: U.S. Policy Will Decide U.S.-China Race for Biotech Leadershipyahoo . Key findings include:

• 77% said a stable FDA and better guidance would increase investmentIncubate Investor Survey: U.S. Policy Will Decide U.S.-China Race for Biotech Leadershipyahoo
• 73% said the ORPHAN Cures Act has had a positive impact on their decision to invest in rare disease companiesIncubate Investor Survey: U.S. Policy Will Decide U.S.-China Race for Biotech Leadershipyahoo
• 87% said federal price setting policies such as Most Favored Nation would reduce U.S. biotech investmentIncubate Investor Survey: U.S. Policy Will Decide U.S.-China Race for Biotech Leadershipyahoo

One venture capitalist commented that "regulatory reform at the FDA is a huge positive for life sciences companies"Incubate Investor Survey: U.S. Policy Will Decide U.S.-China Race for Biotech Leadershipyahoo . Another noted that "as interest rates continue to move down, LPs have expressed their desire to seek higher returns through life sciences investments," with the XBI biotech index up 44% since JuneIncubate Investor Survey: U.S. Policy Will Decide U.S.-China Race for Biotech Leadershipyahoo .

The One-Trial Standard's Economic Impact

The FDA's shift to one-trial approvals has immediate financial implications for drug developers. Industry estimates suggest "a single Phase III can cost $30 million–$150 million, with a second study adding comparable costs"Inside Biotech: FDA says ‘one and done’ — what it means for biotech globallyproactiveinvestors . The Pharmaceutical Research and Manufacturers of America (PhRMA) welcomed the change, stating it "has the potential to accelerate biopharmaceutical research and development, getting medicines to patients faster"FDA Allows Single Trial Drug Approvals Starting Now - BioXconomybioxconomy .

However, critics caution that "loosening the default bar could, over time, erode confidence in approvals and lead to greater variability in post-market performance, particularly for drugs addressing broad, common conditions"Inside Biotech: FDA says ‘one and done’ — what it means for biotech globallyproactiveinvestors . One analyst warned that companies conducting only one trial "could actually be assuming additional risk," noting that "we are being hit with regulatory reversals on previously agreed upon programs and endpoints, and so therefore a company could be incurring a much greater fiduciary risk to embark on only one study"FDA’s One Trial Policy Not a Revolution but a Potentially Risky Evolution - BioSpacebiospace .

Priority Review Voucher Program Economics

The Rare Pediatric Disease Priority Review Voucher (PRV) program—reauthorized through September 30, 2029 under the Consolidated Appropriations Act of 2026Congress Extends Rare Pediatric Disease Priority Review Voucher Program Through 2029 - Spencer Fanespencerfane —remains a critical financing mechanism for neurodevelopmental therapies. Recent PRV transactions demonstrate substantial values:

Congress Reauthorizes Pediatric Priority Review Voucher Program in FY2026 Budget — Renewed Incentives for Rare Pediatric Drug Development (FDA/Life Sciences) | Lowenstein Sandler LLPlowenstein

To date, 53 PRVs have been awarded across 39 rare pediatric diseases, and prior to the creation of the RPD PRV program, only 3 of those 39 diseases had any FDA-approved treatmentThe Cost of PRV Inactionbio . An RDCC analysis found that "200 therapies are at risk of losing eligibility for a PRV if the program is not reauthorized," translating to "an estimated $4 billion in lost reinvestment potential"Rare Disease Biotechs Stand To Lose $4B if Priority Voucher Program Not Reinstated: Report - BioSpacebiospace .

The program's importance for small biotechs is substantial: "holding or selling a PRV can be transformative for small and mid-size biotechs, attracting investment or providing critical capital to fund additional R&D"The Cost of PRV Inactionbio . As one rare disease executive explained, "if this rare disease voucher program is removed, you're going to watch many of the smaller programs—[with] 10,000 or less patients—be cut"Rare Disease Biotechs Stand To Lose $4B if Priority Voucher Program Not Reinstated: Report - BioSpacebiospace .

However, the Commissioner's National Priority Voucher (CNPV) program launched in June 2025 operates differently: CNPVs are "non-transferable, expire within two years, and are awarded at the Commissioner's discretion. While CNPVs promise ultra-fast 1–2 month reviews, they offer zero value in terms of financing—eliminating the monetization that made rare disease development economically viable for venture-backed companies"The FDA Reset and its Ripple Effect on European Biotech - V-Biov-bio .

Neurodevelopmental Therapeutics Investment Activity

Current Funding Landscape

Despite regulatory uncertainty, capital continues to flow into neurodevelopmental therapeutics:

NeuroNOS secured $2 million in equity financing in March 2025 to accelerate preclinical development of a nitric oxide-regulating therapy for autism spectrum disorder, with first-in-human studies anticipated in 2026NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapyglobenewswire . The company subsequently received FDA Orphan Drug Designation for Phelan-McDermid Syndrome, providing "seven years of market exclusivity upon approval, tax credits for qualified clinical trials, waiver of FDA application fees, and access to FDA protocol assistance"NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autismglobenewswire .

The Autism Impact Fund closed its first fund at $60 million (above its $50 million target) with 16 portfolio companies spanning "technology, tech-enabled services, life sciences, and care delivery models, as well as platforms for improving diagnosis, access to care, precision therapeutics, digital health tools"This VC Fund Is Backing the Next Generation of Autism Breakthroughs – and Investors Are Taking Noticeyahoo . The fund has achieved two exits: Joshin (sold to Rethink/K1) and Spectrum AI (sold to Central Reach/Roper)This VC Fund Is Backing the Next Generation of Autism Breakthroughs – and Investors Are Taking Noticeyahoo .

Kingdom Therapeutics partnered with 5 Horizons Capital to advance its ASD therapeutic candidate KT-20610 into randomized, placebo-controlled, multicenter studies, with 5 Horizons providing "capital and strategic support to advance innovative therapies"Kingdom Therapeutics Selects Novotech as CRO for Groundbreaking Autism Clinical Trials Facilitated by 5 Horizons Capital | Kingdom Therapeuticskingdomtherapeutics .

MindMed is developing MM402 (R(-)-MDMA) for autism spectrum disorder, having completed Phase 1 studies in healthy volunteersMindMed Reports First Quarter 2025 Financial Results and Recent Business Updatesfinancialpost . The company maintains $245.5 million in cash, cash equivalents, and investments as of March 2025, sufficient to fund operations into 2027MindMed Reports First Quarter 2025 Financial Results and Recent Business Updatesfinancialpost .

CAMP4 Therapeutics is advancing CMP-SYNGAP-01 for SYNGAP1-related disorders (a rare neurodevelopmental condition), with GLP toxicology studies supporting a planned Phase 1/2 clinical trial as early as the second half of 2026CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01globenewswire . The company entered a strategic collaboration with GSK to advance targets identified by its RAP platformCAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestonesglobenewswire .

Clinical Pipeline Expansion

DelveInsight's autism spectrum disorder pipeline analysis identified "20+ active players working to develop 22+ pipeline autism spectrum disorder drugs"Autism Spectrum Disorder Clinical Trial Analysis: Keyglobenewswire . Key programs include:

Autism Spectrum Disorder Clinical Trial Analysis: Keyglobenewswire +1

Neurotech International received Human Research Ethics Committee approval in February 2026 to commence its Beyond Harmony Phase 3 clinical study of NTI164 in ASD Levels 2 and 3, designed to support regulatory submissions to both Australia's TGA and the U.S. FDAApproval received for NTI164 Phase 3 Clinical Study in ASD - Neurotech International Limited (ASX:NTI) - Listcorp.listcorp .

Yamo Pharmaceuticals reported positive Phase II results for L1-79 in May 2025, showing "statistically significant and clinically meaningful improvements in the Vineland-3 Socialization Standard Score (VSSS) and several secondary outcome measures"Autism Spectrum Disorder Clinical Trial Analysis: Keyglobenewswire .

Market Valuation Context

The autism spectrum disorder therapeutics market was valued at $5,184.83 million in 2025, projected to grow at a CAGR of 5.9% to reach $7,719.17 million by 2032Autism Spectrum Disorder (ASD) Therapeutics Market Insightsreanin . The U.S. autism treatment market was estimated at $4.4 billion in 2024, with forecast annual revenue growth of 3.8% through 2028This VC Fund Is Backing the Next Generation of Autism Breakthroughs – and Investors Are Taking Noticeyahoo .

Private equity activity has been substantial: Brown University researchers identified 574 autism therapy centers owned by private equity firms as of 2024, spanning 42 states, with most acquired between 2018 and 2022 through 142 separate dealsPrivate equity firms acquired more than 500 autism centers in past decade, study shows | Brown Universitybrown . States in the top third for childhood autism prevalence were 24% more likely to have private equity-owned clinicsPrivate equity firms acquired more than 500 autism centers in past decade, study shows | Brown Universitybrown .

Venture capital in neurology more broadly moderated in Q3 2025, with 35 rounds raising $1.3 billion compared to $1.9 billion in Q2Neurology R&D Partnerships, M&A and Venture Funding - Q3 2025 Review - DealFormadealforma . Notable investments included MapLight Therapeutics' $373 million Series DNeurology R&D Partnerships, M&A and Venture Funding - Q3 2025 Review - DealFormadealforma .

Strategic Implications for Biotech Investment

Risk-Adjusted Opportunity Assessment

The FDA's evolving regulatory posture creates a bifurcated investment landscape:

Lower Development Costs, Higher Regulatory Uncertainty: The one-trial policy and expanded real-world evidence acceptance could reduce Phase 3 costs by $30-150 million per avoided trialInside Biotech: FDA says ‘one and done’ — what it means for biotech globallyproactiveinvestors . However, as one industry analyst noted, "regulatory uncertainty dominates valuation. The market reacts sharply to clinical trial results and FDA feedback. Therefore, disclosure and risk management take on existential importance"Duane Morris LLP - Financing and Exit Strategies in Life Sciences: Aligning Capital with Compliance and IP Valueduanemorris .

Literature-Based Approval Precedent Limited to Ultra-Rare Conditions: The leucovorin case—approval for CFD-FOLR1 affecting ~1 in 1 million while rejecting broader autism claims—suggests that literature-based evidence may support approvals only for genetically defined, mechanistically clear ultra-rare conditions. For broader neurodevelopmental populations, traditional clinical trials remain essential.

PRV Monetization Preserved: The reauthorization of the RPD PRV program through 2029 maintains the $150-200 million non-dilutive financing opportunity for companies achieving rare pediatric disease approvalsCongress Reauthorizes Pediatric Priority Review Voucher Program in FY2026 Budget — Renewed Incentives for Rare Pediatric Drug Development (FDA/Life Sciences) | Lowenstein Sandler LLPlowenstein . This remains a critical component of rare disease investment economics.

Pipeline Diversification Considerations: For European VCs, "success in this environment requires a fundamental shift when considering potential investments: along with scientific merit and market opportunities, regulatory clarity must now also be elevated to a primary criterion. Investors should also construct diversified portfolios that include a balance of modalities and geographic strategies, and account for extended capital runways that assume regulatory delays"The FDA Reset and its Ripple Effect on European Biotech - V-Biov-bio .

The Leucovorin Case as Investment Signal

The leucovorin regulatory trajectory offers several lessons for neurodevelopmental therapeutics investors:

1. Initial FDA enthusiasm does not guarantee broad approval. The gap between Commissioner Makary's September 2025 statements ("hundreds of thousands of kids... will benefit") and the March 2026 reality (indication limited to ~1 in 1 million patients) demonstrates that public announcements may overstate ultimate regulatory scope.

2. Literature-based evidence has boundaries. Even under an FDA leadership explicitly committed to "repurposing older medications for chronic diseases," the evidentiary bar for broader indications remains substantial. The retraction of key supporting studies directly impacted the final approval scope.

3. Ultra-rare genetic conditions represent a distinct regulatory category. The CFD-FOLR1 approval on case report evidence may not translate to conditions with less mechanistically defined populations. Investors should differentiate between genetically stratified conditions and heterogeneous neurodevelopmental phenotypes.

4. Regulatory developments require real-time monitoring. The five-month evolution from September 2025 announcement to March 2026 approval fundamentally altered the commercial profile of the indication. Companies and investors operating on initial announcements may miscalculate opportunity scale.

Forward-Looking Investment Considerations

The broader FDA policy environment—combining one-trial defaults, real-world evidence expansion, and an explicit drug repurposing agenda—creates potential opportunities for capital-efficient development strategies in neurodevelopmental therapeutics, particularly for:

• Genetically defined neurodevelopmental conditions where mechanistic clarity supports literature-based or single-trial regulatory strategies
• Programs targeting rare pediatric disease designations that preserve PRV eligibility through September 2029
• Drug repurposing candidates with established safety profiles and emerging efficacy evidence in specific neurodevelopmental subpopulations
• Companies with sufficient capital runway to accommodate potential regulatory timeline variability

However, the leucovorin case underscores that policy rhetoric may diverge from regulatory outcomes. Investment strategies predicated on aggressive regulatory assumptions should incorporate scenarios where evidence requirements ultimately exceed initial expectations—a risk that the five-month leucovorin trajectory made tangibly concrete.